Advanced search
Publication Cover
Hepatic Oncology Volume 7, 2020 - Issue 2
Submit an article Journal homepage
699
Views
0
CrossRef citations to date
0
Altmetric
Editorial

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance

Devis Pascut1 Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149Trieste, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0583-1973View further author information
ORCID Icon,
Muhammad Yogi Pratama1 Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149Trieste, Italy;2 Universitas Hasanuddin, Faculty of Medicine, Makassar, 90245, IndonesiaView further author information
&
Claudio Tiribelli1 Fondazione Italiana Fegato – ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149Trieste, ItalyORCID Iconhttps://orcid.org/0000-0001-6596-7595View further author information
ORCID Icon
Article: HEP21 | Received 31 Mar 2020, Accepted 06 May 2020, Published online: 22 Jun 2020

References

  • WelzelTM, NelsonDR, MorelliGet al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut66(10), 1844–1852 (2017).
  • ReigM, MariñoZ, PerellóCet al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol.65(4), 719–726 (2016).
  • ContiF, BuonfiglioliF, ScuteriAet al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol.65(4), 727–733 (2016).
  • WaziryR, HajarizadehB, GrebelyJet al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J. Hepatol.67(6), 1204–1212 (2017).
  • MendizabalM, PiñeroF, RidruejoEet al. Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents. Clin. Gastroenterol. Hepatol.doi:10.1016/j.cgh.2020.02.044 (2020) ( Epub ahead of print).
  • IoannouGN, GreenPK, BerryK. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol.68(1), 25–32 (2017).
  • HamdaneN, JühlingF, CrouchetEet al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology156(8), 2313–2329.e7 (2019).
  • KonoM, NishidaN, HagiwaraSet al. Unique characteristics associated with sustained liver damage in chronic hepatitis C patients treated with direct acting antivirals. Dig. Dis.35(6), 556–564 (2017).
  • WatanabeT, TokumotoY, JokoKet al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol. Res.49(2), 136–146 (2019).
  • PelegN, IssacharA, SnehArbib Oet al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J. Viral Hepat.26(11), 1257–1265 (2019).
  • HolmesJA, Carlton-SmithC, KimAYet al. Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. J. Viral Hepat.26(3), 362–372 (2019).
  • DebesJD, van TilborgM, GroothuisminkZMAet al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology154(3), 515–517.e3 (2018).
  • ChuPS, NakamotoN, TanikiNet al. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS ONE12(6), e0179096–e0179096 (2017).
  • FaillaciF, MarziL, CritelliRet al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology68(3), 1010–1024 (2018).
  • VillaniR, FacciorussoA, BellantiFet al. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS ONE11(12), e0167934 (2016).
  • PascutD, CavallettoL, PratamaMYet al. Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals. Cancers (Basel)11(11), pii: E1773 (2019).
  • MückeVT, ThomasD, MückeMMet al. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Liver Int.39(11), 2174–2183 (2019).
  • YasuiY, KurosakiM, KomiyamaYet al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol. Res.48(13), 1131–1139 (2018).
  • BekkiY, YoshizumiT, ShimodaSet al. Hepatic stellate cells secreting WFA+ -M2BP: its role in biological interactions with Kupffer cells. J. Gastroenterol. Hepatol.32(7), 1387–1393 (2017).
  • RuggeriM. Hepatocellular carcinoma: cost–effectiveness of screening. A systematic review. Risk Manag. Healthc. Policy5, 49–54 (2012).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.